Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.59 |
| ▸ | HTR7 | P34969 | 8/20 | 0.56 |
| ▸ | DRD3 | P35462 | 4/20 | 0.53 |
| ▸ | DRD2 | P14416 | 3/20 | 0.53 |
| ▸ | HTR1A | P08908 | 2/20 | 0.53 |
| ▸ | HTR2A | P28223 | 2/20 | 0.53 |
| ▸ | HTR2C | P28335 | 2/20 | 0.53 |
| ▸ | HTR6 | P50406 | 2/20 | 0.53 |
| ▸ | DRD5 | P21918 | 2/20 | 0.52 |
| ▸ | DRD1 | P21728 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5617456 | 0.86 | KCNH2 (0.55) | SIGMAR1HTR7DRD2 | |
| SCHEMBL11465528 | 0.78 | SIGMAR1 (0.76) | SIGMAR1HTR7DRD3DRD2HTR1A | |
| SCHEMBL5617444 | 0.76 | HTR7 (0.49) | SIGMAR1HTR7HTR1AHTR6 | |
| SCHEMBL13875120 | 0.76 | SIGMAR1 (0.69) | SIGMAR1HTR7DRD3DRD2HTR1A | |
| SCHEMBL11405931 | 0.76 | SIGMAR1 (0.69) | SIGMAR1HTR7DRD3DRD2HTR1A | |
| SCHEMBL13875122 | 0.75 | SIGMAR1 (0.71) | SIGMAR1HTR7DRD3DRD2HTR1A | |
| SCHEMBL5617282 | 0.75 | KDM4E (0.54) | DRD3DRD2HTR1AHTR2ADRD1 | |
| SCHEMBL9413482 | 0.75 | HTR7 (0.54) | SIGMAR1HTR7HTR1AHTR2AHTR2C | |
| SCHEMBL2114093 | 0.74 | SIGMAR1 (0.67) | SIGMAR1HTR7DRD3DRD2HTR2A | |
| SCHEMBL9378627 | 0.74 | SIGMAR1 (1.00) | SIGMAR1HTR7DRD3DRD2HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7285553-B2 | Serotonergic 5HT7 receptor compounds for treating ocular and CNS disorders | ALCON MANUFACTURING, LTD. (US) | 2007-10-23 | — | — | US | disclosed |
| US-7060704-B2 | Serotonergic 5HT7 receptor compounds for treating ocular and CNS disorders | ALCON MANUFACTURING, LTD. (US) | 2006-06-13 | — | — | US | disclosed |
| US-20060052372-A1 | Serotonergic 5HT7 receptor compounds for treating ocular and CNS disorders | ALCON RESEARCH, LTD. | 2006-03-09 | — | — | US | disclosed |
| US-6960579-B1 | Serotonergic 5HT7 receptor compounds for treating ocular and CNS disorders | ALCON MANUFACTURING, LTD. (US) | 2005-11-01 | — | — | US | disclosed |
| US-20050187214-A1 | Serotonergic 5HT7 receptor compounds for treating ocular and CNS disorders | ALCON RESEARCH, LTD. | 2005-08-25 | — | — | US | disclosed |
| EP-1079763-A2 | SEROTONERGIC 5HT 7? RECEPTOR COMPOUNDS FOR TREATING OCULAR AND CNS DISORDERS | ALCON LABORATORIES, INC. (US) | 2001-03-07 | — | — | EP | disclosed |
| WO-1999059499-A2 | SEROTONERGIC 5HT7 RECEPTOR COMPOUNDS FOR TREATING OCULAR AND CNS DISORDERS | ALCON LABORATORIES, INC. (US) | 1999-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060052372-A1 | Serotonergic 5HT7 receptor compounds for treating ocular and CNS disorders | HTR7, HTR1A, HTR2B | SIGMAR1 270/4885HTR7 1/4885DRD3 52/4885 |
| US-20050187214-A1 | Serotonergic 5HT7 receptor compounds for treating ocular and CNS disorders | HTR7, HTR1A, HTR2B | SIGMAR1 270/4885HTR7 1/4885DRD3 52/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.